MCK

McKesson Corporation Common Stock (MCK)

Stock · NYSE · Health Care

$893.39as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 29, 2026

McKesson Expands Into Precision Medicine With Acquisition. McKesson has agreed to acquire Precision Medicine Group, a move aimed at strengthening its clinical research and commercialization capabilities. The deal signals McKesson's intent to grow in higher-value specialty services rather than rely solely on its core drug distribution business. Separately, recent coverage highlighted McKesson's inclusion in dividend-focused stock screeners and reviewed its long-term return profile for shareholders. The acquisition comes as the stock trades well above its 52-week low but below its high, with analysts' average price target sitting above the current price level.

Active signals

Support level
$854
Industry
Other Pharmaceuticals

About MCK

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to r…

Sector
Health Care
Industry
Other Pharmaceuticals
Employees
41,600

Fundamentals

1-day range
$890.8$900.22
Market cap
$99.43B
P/E (trailing)
21.89
P/E (forward)
17.67
EPS (trailing)
$37.35
Dividend yield
0.54%
Beta
0.30
Avg. volume
1.04M
Ex-dividend date
September 1, 2026
Dividend pay date
October 1, 2026
52-week range
$677.28$999
Next earnings: November 4, 2026 · EPS estimate $10.76confirmed

How McKesson Corporation Common Stock Makes Money

Where the revenue actually goes — FY2026 annual results

market-wall.comTotalRevenue$403.43BNet Income$4.76B (1%)Cost of Revenue$388.88B (96%)SG&A$8.10B (2%)Tax$1.10B (0%)MCK

Source: 10-K filed May 8, 2026 · via SEC EDGAR / Finnhub

Forecasts

16 analyst ratings

Buy 87%
Hold 13%
Sell 0%
1-year price forecast
High
$1,080
+20.9%
Median
$1,000
+11.9%
Low
$845
-5.4%

McKesson Corporation Common Stock Competitors

Chosen by industry and closest market cap.

  • MCK
    McKesson Corporation Common Stock
    $894.35
    ▲ 0.43%
    Market cap $99.43BP/E 21.89
    $677.28$999
  • COR
    Cencora Inc. Common Stock
    $322.02
    ▲ 0.25%
    Market cap $60.00BP/E 22.54
    $244.82$377.54
  • HLF
    Herbalife Ltd. Common Shares
    $12.43
    ▲ 0.65%
    Market cap $1.32BP/E 7.68
    $7.56$20.4
  • NUS
    Nu Skin Enterprises Inc. Common Stock
    $4.85
    ▲ 2.54%
    Market cap $250.52MP/E 4.30
    $4.49$14.62
  • HKPD
    Cellyan Biotechnology Co. Ltd Class A Ordinary Shares
    $0.36
    ▼ 11.33%
    Market cap $16.93MP/E
    $0.31$1.82
  • SCNX
    Scienture Holdings Inc. Common Stock
    $0.3938
    ▲ 3.63%
    Market cap $15.72MP/E
    $0.2382$2.6
  • COSM
    Cosmos Health Inc. Common Stock
    $0.225
    ▲ 4.17%
    Market cap $14.59MP/E
    $0.1616$1.32

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions
Acquired
3.1K
Disposed
22.2K

Institutional Ownership

March 31, 2026

Total shares held
99.69M
Total value held
$82.65B
Institutional holders
2009
Top holders this quarter
  • Unknown11.43M
  • Unknown7.96M
  • Unknown5.73M
  • Unknown3.60M
  • Unknown3.06M
  • Unknown2.90M
  • Unknown2.90M
  • Unknown2.30M
  • Unknown2.24M
  • Unknown1.54M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.